A naukri.com initiative
Bioengineer
2w
154
Image Credit: Bioengineer
PD-1 Inhibitors Extend Survival Post-Chemo Progression
- A recent study in BMC Cancer explores the efficacy of continuing PD-1 inhibitors after disease progression in metastatic gastric cancer (MGC) patients post first-line chemoimmunotherapy.
- Metastatic gastric cancer, known for its aggressiveness, has seen advancements with PD-1 inhibitors alongside chemotherapy, offering improved survival prospects.
- The study compared patients who continued PD-1 inhibitors post-progression (TBP group) with those who did not (NTBP group) to assess survival outcomes.
- Continuing PD-1 inhibitors after progression showed a significant survival advantage with nearly doubled median overall survival and extended progression-free survival.
- Multivariate analysis identified continuing immunotherapy as an independent prognostic factor for both progression-free and overall survival.
- Subgroup analyses suggested specific patient profiles benefiting more from continued PD-1 blockade, hinting at personalized treatment approaches.
- The study hints at ongoing immune modulation and cytotoxicity enhancement by PD-1 inhibitors post-progression as potential mechanisms for extended survival.
- The findings advocate for prospective trials to confirm the benefits of maintenance PD-1 blockade in refractory MGC and emphasize the importance of personalized treatment planning.
- Exploration for biomarkers predicting responsiveness to continued PD-1 inhibition is crucial for effective patient stratification in advanced gastric cancer management.
- The study's outcomes may influence clinical guidelines, emphasizing the role of immune checkpoint inhibitors beyond initial progression in refractory MGC treatment.
Read Full Article
9 Likes
For uninterrupted reading, download the app